3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Renal Cell
11
Carcinoma, Hepatocellular
10
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasms
6
Melanoma
4
Endometrial Neoplasms
3
Uveal Melanoma
2
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Neuroendocrine Tumors
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Kidney Neoplasms
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Adenoid Cystic
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Ovarian Clear Cell Carcinoma
1
Non-squamous Non-small-cell Lung Cancer
1
NSCLC
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
pembrolizumab
29
Carboplatin
27
Specimen Handling
21
durvalumab
20
Pemetrexed
18
Cisplatin
17
Paclitaxel
16
atezolizumab
15
Nivolumab
15
Magnetic Resonance Spectroscopy
15
osimertinib
11
Radiosurgery
11
Radiotherapy
10
Immunoglobulin G
10
Etoposide
10
Docetaxel
10
Disulfides
10
Radiation
9
Taxes
8
Gemcitabine
8
Biopsy
8
Blood Specimen Collection
7
Standard of Care
6
Practice Guidelines as Topic
6
Ipilimumab
6
Surveys and Questionnaires
5
Platinum
5
Bronchoscopy
5
Bevacizumab
5
Ramucirumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lung Neoplasms
×
lenvatinib
×
Clear all
NCT05384015
2026-04-30
PEERS
Fundación GECP
Phase 2
Active not recruiting
46 enrolled